On December 31, 2021, Charles H. Randall, chief strategy officer of SAB Biotherapeutics, Inc. resigned. The company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 USD | -2.05% |
|
-7.42% | -58.25% |
Jul. 01 | SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell 3000E Index | CI |
Jul. 01 | SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.25% | 26.49M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics, Inc. Announces Resignation of Charles H. Randall as Chief Strategy Officer